1946例肿瘤患者化疗及相关药品不良反应临床分析  

Clinical analysis of 1946 cases of adverse drug reactions associated with chemotherapy in cancer patients

作　　者：王睿晴 张艳华[1] 刘红[1] 

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 [2]北京大学医学部药学院临床药学与药事管理系,北京100191

出　　处：《中国药物应用与监测》2018年第1期36-39,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的:分析肿瘤患者药品相关不良反应的发生率及影响因素,为临床肿瘤治疗合理用药提供有效依据。方法:对2011–2016年我院药品不良反应报告进行回顾性分析,包括发生ADR的患者性别、年龄、给药途径、引起ADR的药品分类、引起ADR的药品排名顺序、ADR种类等。结果:2011–2016年共上报1946例ADR,男女比例为1:1.02;ADR发生年龄多数集中在51~60岁,共计590例(30.32%);引发ADR最多的药物为紫杉醇,共计328例(11.57%),引发ADR最多的给药途径为静脉滴注,共计2338例次(82.47%);ADR累及的系统/器官损害共计2696例次,包括全身性损害、血液系统损害、皮肤及其附件损害等。结论:临床应结合相关数据结果,重视肿瘤治疗过程中相关因素引发ADR,定期监测与报告,减少ADR的发生。Objective： To analyze the incidence and infuence factors of adverse drug reaction （ADR） in cancer patients, and provide an effective basis for rational use of drugs in clinical oncology. Methods： The adverse drug reaction reports in our hospital during 2011 – 2016 were analyzed retrospectively, including the age and gender of the patients, the route of administration, the classifcation and ranking of drugs causing ADR, and the type of ADR. Results： There were 1946 cases of ADR in 2011 – 2016. In 6 years, the proportion of men and women was 1 ： 1.02; the age of patients with ADR mostly concentrated in the 51 – 60 years old （590 cases, 30.32%）; paclitaxel associated ADR were the most （328 cases, 11.57%）, the most route of administration of those ADRs was intravenous infusion （2338 cases, 82.47%）; the system and organ damages were involved in 2696 cases of ADR, including systemic damage, blood system damage, damage of skin and its accessories, etc. Conclusion： The clinical data should be combined with the results of relevant data, and the related factors of ADR in the process of cancer treatment should be paid attention to. The regular monitoring and reporting should be paid attention in order to reduce the occurrence of ADR.

关 键 词：抗肿瘤药物 药品不良反应 合理用药 

分 类 号：R969.3[医药卫生—药理学]